Exploring the use of F-choline PET imaging for various medical conditions
Official title: Choline-PET: Exploratory Study Assessing the Potential Role of F-choline PET Imaging in New and Emerging Indications
Run by Centre hospitalier de l'Université de Montréal (CHUM) · NCT04999215 · Data updated 2026-11-12
This study is testing if F-choline PET imaging can help diagnose certain cancers and other medical conditions better than current imaging methods.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Status | Recruiting |
| Started | August 1, 2022 |
| Main results expected | July 1, 2032 |
| Study ends | August 1, 2032 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT04999215 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with known or suspected conditions where F-choline PET imaging may provide valuable clinical insights.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or have known allergies to F-choline will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the diagnostic performance of F-choline PET imaging in patients with known or suspected conditions that may benefit from this imaging technique. F-choline is a radiotracer that has shown promise in visualizing choline metabolism, which is often elevated in certain cancers and medical conditions. The study aims to assess its effectiveness compared to existing imaging methods, particularly in cases involving prostate cancer, parathyroid adenomas, cervical cancers, and liver cancers. Participants will receive an intravenous injection of F-choline to evaluate its potential clinical utility.
Why it matters
Potential benefit: If successful, this study could enhance diagnostic accuracy and treatment planning for patients with specific cancers and conditions.
How similar studies have gone: While F-choline has been studied in prostate cancer, its broader applications in other conditions are still emerging and not yet fully validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any patient with a known or suspected condition in which F-choline PET imaging might provide clinically useful information. Exclusion Criteria: * Pregnancy * Breastfeeding woman, unwilling to discontinue breastfeeding for 48 hours * Known allergy to F-choline or any excipients * Pediatric patient (\< 18 years old)
Where it's running
-
Centre Hospitalier de l'université de Montréal
Montreal, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Daniel Juneau, MD — Centre hospitalier de l'Université de Montréal (CHUM)
- Study coordinator: Daniel Juneau, MD
- Email: daniel.juneau@umontreal.ca
- Phone: 1-514-890-8180
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.